References
- Abaci A., Saygi M., Yis U., Demir K., Dirik E., Bober E.: Metabolic alterations during valproic acid treatment: a prospective study. Pediatr. Neurol., 2009, 41: 435–439. doi: 10.1016/j.pediatrneurol.2009.06.00.
- Alphonse P.A.S., Ramprasath V., Jones P.J.H.: Effect of dietary cholesterol and plant sterol consumption on plasma lipid responsiveness and cholesterol trafficking in healthy individuals. British Journal of Nutrition, 2017, 117: 56–66. doi: 10.1017/S0007114516004530.
- Annegers J.F., Hauser W.A., Shirts S.B.: Heart disease mortality and morbidity in patients with epilepsy. Epilepsia, 1984, 25: 699–704.
- Antuna-Puentea B., Feve B., Fellahi S., Bastard J.P.: Adipokines: The missing link between insulin resistance and obesity. Diabetes & Metabolism, 2008, 34: 2–11. doi:10.1016/j.diabet.2007.09.004.
- Auley M.T.M., Mooney K.M.: Computationally Modelling Lipid Metabolism and Aging: A Mini-review. Computational and Structural Biotechnology Journal, 2015, 13, 38–46. doi: 10.1016/j.csbj.2014.11.006.
- Bacloer E., Kosari S., Stebbing M.J.: Resistin, an adipokine with non-generalized actions on sympathetic nerve activity. Frontier in Physiology, 2015, 6: 321. doi: 10.3389/fphys.2015.00321.
- Belcastro V., D’Egidio C., Striano P., Verrotti A.: Metabolic and endocrine effects of valproic acid chronic treatment. Epilepsy Research, 2013, 107: 1–8. doi: 10.1016/j.eplepsyres.2013.08.016.
- Berenson G.S., Wattigney W.A., Tracy R.E., Newman W.P. 3rd, Srinivasan S.R., Webber L.S. et al.: Atherosclerosis of the aorta and coronary arteries and cardiovascular risk factors in persons aged 6 to 30 years and studied at necropsy (The Bogalusa Heart Study). Am. J. Cardiol., 1992, 70: 851–858.
- Chen S., Wu H., Klebe D., Hong Y., Zhang J.: Valproic acid: a new candidate of therapeutic application for the acute central nervous system injuries. Neurochem. Res., 2014, 39: 1621–1633. doi: 10.1007/s11064-014-1241-2.
- Egger J., Brett E.M.: Effects of sodium valproate in 100 children with special reference to weight. Br. Med. J., (Clin. Res. Ed.), 1981, 283: 577–581.
- Erdemir A., Cullu N., Yis U., Demircioglu F., Kir M., Cakmakci H. et al.: Evaluation of serum lipids and carotid artery intima media thickness in epileptic children treated with valproic acid. Brain & Development, 2009, 31: 713–716. doi: 10.1016/j.braindev.2008.11.001.
- Evans J.L., Goldfine I.D., Maddux B.A., Grodsky G.M.: Are oxidative stres-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction? Diabetes, 2003, 52: 1–8. doi: 10.2337/diabetes.52.1.1.
- Fan H.C., Lee H.S., Chang K.P., Lee Y.Y., Lai H.C., Hung P.L.: The impact of anti-epileptic drugs on growth and bone metabolism. Internat Journal of Molecular Sciences, 2016, 17: 1–22. doi:10.3390/ijms17081242
- Ghodke-Puranik Y., Thorn C.F., Lamba J.K., Leeder J.S., Song W., Birnbaum A.K. et al.: Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics, 2013, 23: 236–241. doi: 10.1097/FPC.0b013e32835ea0b2.
- Grootaert C., Van der Wiele T., Verstraete W., Bracke M., Vanhoecke B.: Angiopoietin-like protein 4: health effects, modulating agents and structure-function relationship. Expert Review of Proteomics, 2012, 9: 181–199. doi:10.1586/epr.12.12.
- Huang X., Yang Z.: Resistin’s, obesity, and insulin resistance: the continuing disconnect between rodents and humans. J. Endocrinol. Invest., 2016, 39: 607–615. doi: 10.1007/s40618-015-0408-2.
- Klepper J., Voit T.: Facilitated glucose transporter protein type 1 (GLUT1) deficiency syndrome: impaired glucose transport into brain – a review. Eur. J. Pediatr., 2002, 161: 295–304. doi: 10.1007/s00431-002-0939-3.
- Li Y., Ding L., Hassan W., Abdelkader D., Shang J.: Adipokines and hepatic insulin resistance. Journal of Diabetes Research, 2013, Article ID 170532. doi: 10.1155/2013/170532.
- Li Y., Teng C.: Angiopoetin-like proteins 3, 4, and 8: regulating lipid metabolism and providing new hope for metabolic syndrome. Journal of Drug Targeting, 2014, 22: 679–687. doi: 10.3109/1061186X.2014.928715.
- Luo X., Zhang M., Deng L., Zhao J.: Effects of valproate on the carotid artery intima-media thickness in epileptics. Indian Journal of Pharmacology, 2015, 47: 45–48. doi: 10.4103/0253-7613.150328.
- Nagasawa S.Y., Okamura T., Iso H., Tamakoshi A., Yamada M., Watanabe M. et al.: Relation between serum total cholesterol level and cardiovascular disease stratified by sex and age group: a pooled analysis of 65 594 individuals from 10 cohort studies in Japan. J. Am. Heart Assoc., 2012, 1: e001974. doi: 10.1161/JAHA.112.001974.
- Park H.K., Kwak M.K., Kim H.J., Ahima R.S.: Linking resistin, inflammation and cardiometabolic diseases. Korean J. Intern. Med., 2017, 32: 239–247. doi: 10.3904/kjim.2016.229.
- Płonka-Półtorak E., Zagrodzki P., Kryczyk-Kozioł J., Westermarck T., Kaipainen P., Kaski M., Atroshi F.: Does valproate therapy in epileptic patients contribute to changing atherosclerosis risk factors? The role of lipids and free fatty acids. Pharmacological Reports, 2016, 68: 1339–1344. doi: 10.1016/j.pharep.2016.09.001.
- Sakakura K., Nakano M., Otsuka F., Ladich E., Kolodgie F.D., Virmani R.: Pathophysiology of atherosclerosis plaque progression. Heart, Lung, and Circulation, 2013, 22: 399–411. doi: 10.1016/j.hlc.2013.03.001.
- Silva M.F., Aires C.C., Luis P.B., Ruiter J.P., Jist L.I., Duran M. et al.: Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. J. Inherit. Metab. Dis., 2008, 31: 205–216. doi: 10.1007/s10545-008-0841-x.
- Sozio M.S., Liangpunsakul S., Crabb D.: The role of lipid metabolism in the pathogenesis of alcoholic and nonalcoholic hepatic steatosis. Seminars in Liver Disease, 2010, 30: 378–390. doi: 10.1055/s-0030-1267538.
- Terbach N., Williams R.S.: Structure-function studies for the panacea, valproic acid. Biochemical Society Transaction, 2009, 37: 1126–1132. doi: 10.1042/BST0371126.
- Titchenell P.M., Lazar M.A., Birnbaum M.J.: Unraveling the regulation of hepatic metabolism by insulin. Trends in Endocrinology & Metabolism, 2017, 28: 497–505. doi: 10.1016/j.tem.2017.03.003.
- Tomson T., Battino D., Perucca E.: Valproic acid after five decades of use in epilepsy: time to reconsider the indications of time-honoured drug. Lancet Neurol., 2016, 15: 210–218. doi: 10.1016/S1474-4422(15)00314-2.
- Tseng J.H., Chen C.Y., Chen P.C., Hsiao S.H., Fan C.C., Liang Y.C., Chen C.P.: Valproic acid inhibits glioblastoma multiforme cell growth via paraoxonase 2 expression. Oncotarget, 2017, 8: 14666-14679. doi: 10.18632/oncotarget.14716.
- Verrotti A., Torre R.L., Trotta D., Mohn A., Chiarelli F.: Valproate-induced insulin resistance and obesity in children. Horm. Res., 2009, 71: 125–131.
- Wahyuni K.D., Was’an M.: Korelasi antara Durasi Terapi Obat Antiepilepsi Generasi Pertama dengan Kadar Profil Lipid pada Penyandang Epilepsi Idiopatik. Postgraduate Thesis, Universitas Gajah Mada, 2013, Yogyakarta Indonesia.
- Wang Y., Ma X.L., Lau W.B.: Cardiovascular adiponectin resistance: the critical role of adiponectin receptor modification. Trends in Endocrinology & Metabolism, 2017, 28: 519–530. doi: 10.1016/j.tem.2017.03.004.